Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582229 | 0.71 | GSK3A (0.35) | GSK3BGSK3A | |
| SCHEMBL1649991 | 0.67 | GSK3B (0.32) | GSK3B | |
| SCHEMBL3414157 | 0.67 | ALOX15 (0.33) | GSK3BGSK3A | |
| SCHEMBL11061537 | 0.62 | PTGS2 (0.46) | GSK3BGSK3A | |
| SCHEMBL10618947 | 0.61 | CRBN (0.37) | GSK3B | |
| SCHEMBL708902 | 0.59 | — | — | |
| SCHEMBL6851025 | 0.58 | GSK3B (0.44) | GSK3BGSK3ACCR6 | |
| SCHEMBL14964727 | 0.57 | TDP2 (0.38) | — | |
| SCHEMBL6036381 | 0.57 | CRBN (0.33) | — | |
| SCHEMBL41851 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110734434-B | Method for preparing lurasidone and salt thereof | 湖南洞庭药业股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-5185158-A | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same | ALZA CORPORATION (US) | 1993-02-09 | — | — | US | claimed |
| CN-119954815-A | Synthesis method of lurasidone hydrochloride intermediate | 山东科新药业有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-118724791-A | Preparation method of cis-5-exo-2, 3-dicarboximide pharmaceutical intermediate | 四川健腾药业有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-110734434-B | Method for preparing lurasidone and salt thereof | 湖南洞庭药业股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-110734434-B | Method for preparing lurasidone and salt thereof | 湖南洞庭药业股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-10196400-B2 | Process for the preparation of lurasidone and its intermediate | Piramal Enterprises Limited (IN) | 2019-02-05 | — | — | US | disclosed |
| WO-2018023009-A1 | DEUTERATED LURASIDONE | CONCERT PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20170349601-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE AND ITS INTERMEDIATE | Piramal Enterprises Limited (IN) | 2017-12-07 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1379249-A4 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-01-09 | — | — | EP | disclosed |
| US-5858407-A | Method for administering tandospirone | ALZA CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0681473-B1 | COMPOSITIONS CONTAINING TANDOSPIRONE OR ITS ANALOGS | ALZA CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5688518-A | Antidepressive therapy | ALZA CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0681473-A1 | COMPOSITIONS CONTAINING TANDOSPIRONE OR ITS ANALOGS | ALZA CORPORATION (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994016699-A1 | COMPOSITIONS CONTAINING TANDOSPIRONE OR ITS ANALOGS | ALZA CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5330762-A | Tandospiaine antidepressive therapy | ALZA CORPORATION (US) | 1994-07-19 | — | — | US | disclosed |
| US-5246711-A | Dosage form for treating dysthymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5246710-A | Dosage form for treating cyclothymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5185158-A | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same | ALZA CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349601-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE AND ITS INTERMEDIATE | ADH1C, ADH1A, AVPR2 | GSK3B 4295/4885GSK3A 4402/4885CCR6 2405/4885 |
| US-10196400-B2 | Process for the preparation of lurasidone and its intermediate | ADH1C, ADH1A, OPRM1 | GSK3B 3890/4885GSK3A 4088/4885CCR6 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.